Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ ... was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Our IND for RTX-240, our first oncology candidate for the treatment of solid tumors, has been cleared by the FDA. Additionally, we plan to file an IND for RTX-321 for the treatment of HPV-positive tumors by year-end. For more information, please visit us at www.rubiustx.com or follow us on Twitter. read more